Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 22:43 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Intracoronary Administration of Levosimendan in Cardiac Surgery Patients
NCT01500785 · Tampere University Hospital · PHASE4 · terminated · last registry update 2019-09-13 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Change of schedule” | – | Registry record, Tampere University Hospital |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against PDE3A within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2020-09-09Phase 3 first posted: Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA, Ensifentrine + Placebo (NCT04542057)
- 2020-09-02Phase 3 first posted: Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA, Ensifentrine + Placebo (NCT04535986)
- 2020-07-28Results posted on the registry: MediciNova, ibudilast + Placebo oral capsule (NCT01982942)
- 2020-04-29Phase 3 first posted: Ain Shams University, Pentoxifylline (NCT04367935)
- 2020-04-27Phase 3 first posted: University Hospital, Angers, Milrinone 1 Mg/mL Solution for Injection + Saline solution for injection (NCT04362527)
- 2020-04-24Results posted on the registry: Shire, SPD422 + Omeprazole (NCT03866434)
- 2020-04-01Phase 3 first posted: Medical University of Vienna, Levosimendan + Placebo (NCT04329624)
- 2020-02-26Phase 3 first posted: PharmaEssentia, Ropeginterferon alfa-2b + Anagrelide (NCT04285086)
- 2020-01-03Phase 3 first posted: Tanta University, pentoxyifylline + Mebeverine (NCT04217733)
- 2019-11-27Phase 3 first posted: María de los Ángeles Tena Pajuelo, Levosimendan + Placebos (NCT04179604)
- 2019-11-12Phase 3 first posted: Centre Hospitalier Universitaire Dijon, Levosimendan + Cernevit (NCT04158674)
- 2019-11-06Phase 3 first posted: Erasmus Medical Center, Pentoxifylline (NCT04152980)
- 2019-10-10Results posted on the registry: Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA, RPL554 Suspension + Placebo (NCT03673670)
- 2019-08-15Phase 3 first posted: MediciNova, MN-166 + placebo (NCT04057898)
- 2019-07-16Phase 3 first posted: Pr Bruno LEVY, Levosimendan 2.5 MG/ML Injectable Solution + Placebo (NCT04020263)
- 2019-07-15Phase 3 first posted: Shenzhen Second People's Hospital, Levosimendan (NCT04020003)
- 2019-07-02Results posted on the registry: Indiana University, Milrinone + Placebo (NCT02712788)
- 2019-07-02Also stopped (terminated): Indiana University, Milrinone + Placebo (NCT02712788)
- 2019-06-04Results posted on the registry: Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA, RPL554 suspension + Placebo (NCT03443414)
- 2019-05-29Results posted on the registry: Patrick Northup, MD, Pentoxyfylline + Placebo (NCT02123576)
- 2019-05-29Also stopped (terminated): Patrick Northup, MD, Pentoxyfylline + Placebo (NCT02123576)
- 2019-05-16Results posted on the registry: Vanderbilt University Medical Center, Propofol + Sevoflurane (NCT02726620)
- 2019-05-13Phase 3 first posted: Orion Corporation, Orion Pharma, Levosimendan (NCT03948178)
- 2019-03-20Results posted on the registry: Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA, RPL554 + Placebo (NCT02919995)
- 2019-01-30Phase 3 first posted: Shanghai Children's Medical Center, Milrinone + Normal saline (NCT03823781)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision